Alight Launched HRA Product for Weight Loss Drugs
The new health reimbursement account helps employers manage rising costs associated with GLP-1 weight management prescriptions.
Updated on Oct. 13, 2026 in Weight Loss
Live Poll
Should employers be allowed to cap coverage for expensive weight management medications?
Alight has introduced a health reimbursement account (HRA) product specifically designed to fund employee access to GLP-1 weight management medications. This move arrives as companies look to balance rising drug expenses with ongoing employee demand for weight loss treatments.
Why it matters
Many employers are shifting away from open-ended coverage for GLP-1 agonists due to the high monthly costs of branded injectables, which can range from $1,000 to $1,500. By using fixed-contribution HRA models, companies can cap their financial liability while continuing to provide some level of drug access.
GLP-1 drugs represented 42% of prescriptions reviewed for Alight members in 2026, an increase from 32% in 2024. Additionally, 14% of large employers have dropped or plan to drop weight management coverage for these drugs by 2027.
The players
Alight
Alight is a Deerfield, Illinois-based firm providing cloud-based human capital and business solutions for large employers.
The details
The HRA structure allows companies to carve out GLP-1 medications from their main drug plans, funding the costs through a set annual contribution that caps out at $2,200 for 2026. Employers maintain control over eligibility criteria, which represents a broader industry trend where 21% of companies now use integrated HRA or HSA accounts for these costs.
Timeline
GLP-1 drugs accounted for 32% of reviewed prescriptions in 2024.
72% of large employers covered GLP-1 agonists in 2025.
The International Foundation of Employee Benefit Plans conducted a survey from June 2 to June 12, 2026.
WEX introduced a similar GLP-1 HRA product in March 2026.
Alight officially launched its GLP-1 HRA product on October 13, 2026.
The Big Picture
This product aligns with the federal regulatory framework defined by the 2026 contribution cap for an excepted benefit HRA. By utilizing these limits, firms are formalizing a transition away from traditional unlimited pharmacy benefits toward strictly managed, fixed-contribution health models.
Employees may see a shift toward fixed-contribution models where their employer pays a set portion of the drug costs rather than a flat co-pay. This change requires patients to manage their pharmacy expenses more closely against their HRA balance to avoid out-of-pocket costs.
The takeaway
Employers are increasingly treating weight loss medications as a fixed-budget benefit rather than a standard prescription service. Workers should review their benefit summaries to understand how their employer is structuring GLP-1 coverage for the coming year.
What happens next
Approximately 14% of large employers plan to discontinue GLP-1 weight management coverage by 2027.
Further reading
For more on industry shifts regarding medical coverage, visit the Weight Loss section.
Live Poll
Should employers be allowed to cap coverage for expensive weight management medications?
